Showing results (111-120 of 137) with videos related to
Sort By:
Pageof 14
American Journal of Hematology|October 23, 2016
A population-based study of chronic myeloid leukemia patients treated with imatinib in first lineFausto Castagnetti, Francesco Di Raimondo, Antonio De Vivo, et al.Annals of Hematology|October 4, 2017
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter seriesAlessandra Iurlo, Sara Galimberti, Elisabetta Abruzzese, et al.Leukemia Research|December 9, 2015
Dasatinib first-line: Multicentric Italian experience outside clinical trialsMassimo Breccia, Fabio Stagno, Luigiana Luciano, et al.Hematological Oncology|March 21, 2019
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chartGiovanni Caocci, Olga Mulas, Elisabetta Abruzzese, et al.Clinical Lymphoma, Myeloma & Leukemia|February 18, 2024
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment PlanMichele Malagola, Alessandra Iurlo, Cristina Bucelli, et al.Leukemia Research|August 19, 2015
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patientsMassimo Breccia, Fabio Efficace, Simona Sica, et al.Journal of the National Cancer Institute|March 23, 2011
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinibCarlo Gambacorti-Passerini, Laura Antolini, François-Xavier Mahon, et al.Leukemia Research|June 3, 2026
Association of hypomethylating agents + venetoclax in the real-life treatment of Myeloproliferative Neoplasms in blastic phaseRoberto Latagliata, Novella Pugliese, Dorela Lame, et al.International Journal of Cardiology|November 13, 2019
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitorsGiovanni Caocci, Olga Mulas, Mario Annunziata, et al.Cancer Medicine|February 17, 2021
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA studyMichele Malagola, Alessandra Iurlo, Elisabetta Abruzzese, et al.Pageof 14